Sign up to save your podcasts
Or
Share 99. Cyclarity Therapeutics: Revolutionizing Age-Related Disease Treatment through Unique Drug Design
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
99. Cyclarity Therapeutics: Revolutionizing Age-Related Disease Treatment through Unique Drug Design
This episode refers to a number of visuals that are in the video version which can be seen on Spotify: https://open.spotify.com/show/3fbnO3K6fxKt9pfaTp8mYn or on YouTube: https://youtu.be/24FR5Knwvfs
We believe the message is an important one, even if you do not watch the video, and hope that you will enjoy this and every episode of our series.
Dr. Matthew O'Connor, was awarded his master’s degree in neuroscience from Northwestern Medical in 1999 and his Ph.D. in Biochemistry from Baylor College of Medicine in 2005.
His doctoral and postdoctoral research includes work at Baylor College of Medicine and UC Berkeley on telomeres and muscle stem cells in aging.
He is the former VP of Research at SENS Research Foundation (now Lifespan Research Institute), where he oversaw a broad swath of research projects spanning many aspects of rejuvenation biotechnology, from which he authored many papers and patents. Dr. O'Connor co-founded Cyclarity Therapeutics in 2019 to develop drugs targeting molecular toxins that accumulate with age in various cells and tissues. Their first drug product targets oxidized cholesterol in cardiovascular disease.
Cyclarity Therapeutics is a clinical-stage pharmaceutical startup committed to developing drugs to prevent and treat age-related diseases by addressing root causes - the buildup of toxic molecules that accumulate in the body over time. Their current target is atherosclerosis, the culprit behind most cardiovascular disease and stroke deaths worldwide. The company's first product, UDP-003, is a novel therapeutic which is able to bind and extract oxidized cholesterol from cells and tissues to restore their function. This therapeutic has the potential to not only prevent the accumulation of atherosclerotic plaque, but also to reduce plaque which has already accumulated - an ability never before achieved with drug treatment. It also has applications in a range of additional age-related conditions, including neurodegenerative diseases, stroke, age-related macular degeneration, and liver disease. Cyclarity recently launched its first-in-human Phase 1 Clinical Trial in Australia.
Cyclarity has also developed a computational platform for the design of specialized molecules to bind any target of interest. This platform was used to design UDP-003. The company incorporates AI and ML with the goal of automating the process of designing molecules for a range of uses, including anesthesia reversal in surgery, nanoplastic removal, and nutritional modifications for food products. The goal is to use this technology to design molecules to help people across various industries, from medicine to food to the environment, and beyond.
To learn more, go to:
https://cyclaritytx.com/
https://www.linkedin.com/company/cyclarity/
https://m.facebook.com/Cyclarity/
View all episodes
By The Rotary eClub of Silicon ValleyThis episode refers to a number of visuals that are in the video version which can be seen on Spotify: https://open.spotify.com/show/3fbnO3K6fxKt9pfaTp8mYn or on YouTube: https://youtu.be/24FR5Knwvfs
We believe the message is an important one, even if you do not watch the video, and hope that you will enjoy this and every episode of our series.
Dr. Matthew O'Connor, was awarded his master’s degree in neuroscience from Northwestern Medical in 1999 and his Ph.D. in Biochemistry from Baylor College of Medicine in 2005.
His doctoral and postdoctoral research includes work at Baylor College of Medicine and UC Berkeley on telomeres and muscle stem cells in aging.
He is the former VP of Research at SENS Research Foundation (now Lifespan Research Institute), where he oversaw a broad swath of research projects spanning many aspects of rejuvenation biotechnology, from which he authored many papers and patents. Dr. O'Connor co-founded Cyclarity Therapeutics in 2019 to develop drugs targeting molecular toxins that accumulate with age in various cells and tissues. Their first drug product targets oxidized cholesterol in cardiovascular disease.
Cyclarity Therapeutics is a clinical-stage pharmaceutical startup committed to developing drugs to prevent and treat age-related diseases by addressing root causes - the buildup of toxic molecules that accumulate in the body over time. Their current target is atherosclerosis, the culprit behind most cardiovascular disease and stroke deaths worldwide. The company's first product, UDP-003, is a novel therapeutic which is able to bind and extract oxidized cholesterol from cells and tissues to restore their function. This therapeutic has the potential to not only prevent the accumulation of atherosclerotic plaque, but also to reduce plaque which has already accumulated - an ability never before achieved with drug treatment. It also has applications in a range of additional age-related conditions, including neurodegenerative diseases, stroke, age-related macular degeneration, and liver disease. Cyclarity recently launched its first-in-human Phase 1 Clinical Trial in Australia.
Cyclarity has also developed a computational platform for the design of specialized molecules to bind any target of interest. This platform was used to design UDP-003. The company incorporates AI and ML with the goal of automating the process of designing molecules for a range of uses, including anesthesia reversal in surgery, nanoplastic removal, and nutritional modifications for food products. The goal is to use this technology to design molecules to help people across various industries, from medicine to food to the environment, and beyond.
To learn more, go to:
https://cyclaritytx.com/
https://www.linkedin.com/company/cyclarity/
https://m.facebook.com/Cyclarity/